Trial Profile
Bortezomib, cyclophosphamide plusd dexamethasone as induction treatment prior to autologous stem cell transplantation in newly diagnosed multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Jan 2017
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Cyclophosphamide (Primary) ; Dexamethasone (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 16 Jan 2017 Status changed from recruiting to completed.
- 24 Jan 2013 New trial record